Published in Circ Cardiovasc Genet on December 01, 2016
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Discovery and refinement of loci associated with lipid levels. Nat Genet (2013) 7.86
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med (2016) 3.68
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet (2016) 1.71
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med (2013) 1.51
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun (2014) 1.28
Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab (2013) 1.09
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation (2016) 0.97
Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol (2009) 0.94
Current Applications of Genetic Risk Scores to Cardiovascular Outcomes and Subclinical Phenotypes. Curr Epidemiol Rep (2015) 0.91
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ Cardiovasc Genet (2012) 0.88
Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population. Circ Cardiovasc Genet (2015) 0.82
Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. Circ Cardiovasc Genet (2016) 0.79